224 related articles for article (PubMed ID: 31197461)
1. Clinicopathological implications of TIM3
Zhou J; Jiang Y; Zhang H; Chen L; Luo P; Li L; Zhao J; Lv F; Zou D; Zhang Y; Jing Z
Cancer Immunol Immunother; 2019 Jul; 68(7):1157-1169. PubMed ID: 31197461
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic implications of CD8
Zou MX; Guo KM; Lv GH; Huang W; Li J; Wang XB; Jiang Y; She XL
Cancer Immunol Immunother; 2018 Feb; 67(2):209-224. PubMed ID: 29051990
[TBL] [Abstract][Full Text] [Related]
3. High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas.
Ma J; Tian K; Du J; Wu Z; Wang L; Zhang J
J Neurosurg; 2019 Jan; 132(1):140-149. PubMed ID: 30641849
[TBL] [Abstract][Full Text] [Related]
4. Association between Tim‑3 and Gal‑9 expression and gastric cancer prognosis.
Wang Y; Zhao E; Zhang Z; Zhao G; Cao H
Oncol Rep; 2018 Oct; 40(4):2115-2126. PubMed ID: 30106451
[TBL] [Abstract][Full Text] [Related]
5. Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients.
Wang L; Wu Z; Tian K; Wang K; Li D; Ma J; Jia G; Zhang L; Zhang J
J Neurosurg; 2017 Dec; 127(6):1257-1267. PubMed ID: 28059654
[TBL] [Abstract][Full Text] [Related]
6. Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.
Zou MX; Lv GH; Wang XB; Huang W; Li J; Jiang Y; She XL
Neurosurgery; 2019 Jun; 84(6):E318-E333. PubMed ID: 30032257
[TBL] [Abstract][Full Text] [Related]
7. Skull base chordomas: clinical outcome in a consecutive series of 45 patients with long-term follow-up and evaluation of clinical and biological prognostic factors.
Boari N; Gagliardi F; Cavalli A; Gemma M; Ferrari L; Riva P; Mortini P
J Neurosurg; 2016 Aug; 125(2):450-60. PubMed ID: 26745472
[TBL] [Abstract][Full Text] [Related]
8. Expression of the Tim3-galectin-9 axis is altered in drug-induced maculopapular exanthema.
Fernandez-Santamaría R; Palomares F; Salas M; Doña I; Bogas G; Ariza A; Rodriguez-Nogales A; Plaza-Seron MC; Mayorga C; Torres MJ; Fernández TD
Allergy; 2019 Sep; 74(9):1769-1779. PubMed ID: 31034608
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma.
Zhang S; Bai J; Li M; Zhai Y; Wang S; Liu Q; Li C; Gui S; Zhang Y
World Neurosurg; 2019 Sep; 129():e199-e206. PubMed ID: 31125781
[TBL] [Abstract][Full Text] [Related]
10. Male sex as a risk factor for the clinical course of skull base chordomas.
Rachinger W; Eigenbrod S; Dützmann S; Simon M; Feigl GC; Kremenevskaja N; Kretzschmar H; Zausinger S; Kreth FW; Thon N; Tonn JC
J Neurosurg; 2014 Jun; 120(6):1313-20. PubMed ID: 24405075
[TBL] [Abstract][Full Text] [Related]
11. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Luo P; Wang X; Zhou J; Li L; Jing Z
Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T lymphocyte antigen-4 (CTLA-4) expression in chordoma and tumor-infiltrating lymphocytes (TILs) predicts prognosis of spinal chordoma.
He G; Liu X; Pan X; Ma Y; Liu X
Clin Transl Oncol; 2020 Dec; 22(12):2324-2332. PubMed ID: 32504188
[TBL] [Abstract][Full Text] [Related]
13. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma: the significance of CD8
Zhu Q; Yang Y; Chen K; Zhang Q; Huang Y; Jian S
J Transl Med; 2024 Feb; 22(1):174. PubMed ID: 38369502
[TBL] [Abstract][Full Text] [Related]
15. Factors for Overall Survival in Patients with Skull Base Chordoma: A Retrospective Analysis of 225 Patients.
Tian K; Zhang H; Ma J; Wang K; Ru X; Du J; Jia G; Zhang L; Wu Z; Zhang J; Wang L
World Neurosurg; 2017 Jan; 97():39-48. PubMed ID: 27671886
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the BMP4/SMAD signaling pathway in skull base chordomas is associated with poor prognosis.
Feng Y; Zhang Q; Wang Z; Yan B; Wei W; Li P
Int J Clin Exp Pathol; 2015; 8(7):8268-75. PubMed ID: 26339396
[TBL] [Abstract][Full Text] [Related]
17. Factors for tumor progression in patients with skull base chordoma.
Wang L; Tian K; Wang K; Ma J; Ru X; Du J; Jia G; Zhang L; Wu Z; Zhang J
Cancer Med; 2016 Sep; 5(9):2368-77. PubMed ID: 27546605
[TBL] [Abstract][Full Text] [Related]
18. Analysis of clinical factors and PDGFR-β in predicting prognosis of patients with clival chordoma.
Zhai Y; Bai J; Wang S; Gao H; Li M; Li C; Gui S; Zhang Y
J Neurosurg; 2018 Dec; 129(6):1429-1437. PubMed ID: 29303447
[TBL] [Abstract][Full Text] [Related]
19. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics, immunohistochemistry, and outcomes of 77 patients with skull base chordomas.
Ouyang T; Zhang N; Zhang Y; Jiao J; Ren J; Huang T; Chen J
World Neurosurg; 2014; 81(5-6):790-7. PubMed ID: 23298670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]